J&J’s Broad Device Portfolio Eclipses Lackluster Stent Sale Growth
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's medical device and diagnostics revenue grew 11.8% in the second quarter to $4.06 bil., despite a negligible increase in U.S. Cypher drug-eluting stent revenue from the year-ago period